Axonics has announced that the jury has returned a unanimous verdict in the patent infringement lawsuit brought by Medtronic against the company in US District Court for the Central District of California in the USA.
The jury found that Axonics does not infringe any of the three patents-in-suit, according to a recent press release from the company.
“A jury of our peers recognised that Axonics’ proprietary tined lead design and temperature sensor technology is differentiated from our competitor’s intellectual property,” said Raymond W Cohen, chief executive officer of Axonics. “As we have said since this case was first filed in late 2019, our view is that Medtronic’s lawsuit was initiated to stifle competition, limit patient and physician choice, and protect the incumbent’s monopoly in sacral neuromodulation. We are very pleased with the jury’s finding, and continue to remain focused on fulfilling our mission of positively impacting the lives of adults with bladder and bowel dysfunction.”
Axonics’ sacral neuromodulation systems provide adult patients with overactive bladder and/or faecal incontinence with long-lived, easy-to-use, safe, clinically effective therapy, the release further details.
